A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Pristiq® (Desvenlafaxine) Extended-Release Tablets in Generalized Social Anxiety Disorder

NCT01316302 Phase 4 COMPLETED Results posted

This study is designed to evaluate the efficacy and safety of Pristiq® in treatment of the symptoms of Generalized Social Anxiety Disorder (SAD).

Details

Lead sponsor	The Medical Research Network
Phase	Phase 4
Status	COMPLETED
Enrolment	63
Start date	2011-04
Completion	2012-12

Conditions

• Social Anxiety Disorder

Interventions

• Pristiq
• Placebo

Primary outcomes

• Change in the Liebowitz Social Anxiety Scale (LSAS) Total Score — Baseline to study endpoint (Week 12)
  Liebowitz Social Anxiety Scale, measuring social anxiety symptoms; possible total scores ranging from 0-144, with higher scores indicating greater severity of symptoms.

Countries

United States